NRIX - Nurix Therapeutics, Inc.
NEXT EARNINGS:
Apr 14, 2026
EPS Est: $-0.76
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$31.22
DETAILS
HIGH:
$36.00
LOW:
$28.00
MEDIAN:
$30.00
CONSENSUS:
$31.22
UPSIDE:
94.88%
Market Cap:
1.39B
Volume:
910,137
Avg Volume:
1,456,815
52 Week Range:
8.18-22.5
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.97
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
286
IPO Date:
2020-07-24
EPS (TTM):
-3.05
P/E Ratio:
-5.54
Revenue (TTM):
83.98M
Total Assets:
688.13M
Total Debt:
55.73M
Cash & Equiv:
246.96M
Rev Growth (5Y):
36.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-43.8%
Debt/Equity:
0.10
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-01-28 | $-0.82 | $-0.84 | +2.4% | $13.6M | $15.6M | -13.0% |
| 2025-10-09 | $-1.03 | $-0.84 | -22.6% | $7.9M | $12.3M | -35.6% |
| 2025-07-09 | $-0.52 | $-0.71 | +26.8% | $44.1M | $17.5M | +151.6% |
| 2025-04-08 | $-0.67 | $-0.72 | +6.9% | $18.5M | $15.8M | +16.6% |
| 2025-01-28 | $-0.75 | $-0.67 | -11.9% | $13.3M | $14.8M | -10.1% |
| 2024-10-11 | $-0.67 | $-0.67 | 0.0% | $12.6M | $12.8M | -1.7% |
| 2024-07-11 | $-0.71 | $-0.66 | -7.6% | $12.1M | $22.1M | -45.3% |
| 2024-04-10 | $-0.76 | $-0.80 | +5.0% | $16.6M | $17.3M | -4.1% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M | 17.82M | 31.11M | 37.45M |
| Net Income | (264.46M) | (193.57M) | (143.95M) | (180.36M) | (117.19M) | (43.24M) | (21.70M) | (9.43M) |
| EPS | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -0.56 | -0.59 |
| Total Assets | 688.13M | 669.34M | 355.60M | 416.76M | 476.77M | 396.34M | 44.05M | 45.40M |
| Total Debt | 55.73M | 28.30M | 30.61M | 11.96M | 13.04M | 0 | 0 | 0 |
| Cash & Equivalents | 246.96M | 110.00M | 54.63M | 64.47M | 80.51M | 119.36M | 34.82M | 25.59M |
| Operating Cash Flow | (249.47M) | (172.58M) | (81.36M) | (159.81M) | (84.36M) | (80,000) | 601,000 | (31.68M) |
| Free Cash Flow | (263.47M) | (181.86M) | (89.77M) | (172.05M) | (90.03M) | (4.63M) | (1.05M) | (33.27M) |
| FCF per Share | -3.04 | -2.71 | -1.65 | -3.54 | -2.10 | -0.30 | -0.03 | -2.07 |
| Book Value | 538.75M | 526.99M | 200.49M | 303.70M | 342.30M | 290.27M | (57.71M) | (36.85M) |
| Cash & ST Investments | 592.94M | 609.58M | 287.91M | 309.14M | 295.72M | 281.15M | 37.72M | 39.04M |
| ROC Equity | -0.49 | -0.37 | -0.72 | -0.59 | -0.34 | -0.15 | N/A | N/A |